GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (NAS:NVCR) » Definitions » Cyclically Adjusted PB Ratio

NovoCure (NovoCure) Cyclically Adjusted PB Ratio : 5.96 (As of Jul. 16, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Cyclically Adjusted PB Ratio?

As of today (2024-07-16), NovoCure's current share price is $17.99. NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.02. NovoCure's Cyclically Adjusted PB Ratio for today is 5.96.

The historical rank and industry rank for NovoCure's Cyclically Adjusted PB Ratio or its related term are showing as below:

NVCR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4   Med: 5.23   Max: 7.67
Current: 5.96

During the past years, NovoCure's highest Cyclically Adjusted PB Ratio was 7.67. The lowest was 4.00. And the median was 5.23.

NVCR's Cyclically Adjusted PB Ratio is ranked worse than
83.75% of 480 companies
in the Medical Devices & Instruments industry
Industry Median: 1.945 vs NVCR: 5.96

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NovoCure's adjusted book value per share data for the three months ended in Mar. 2024 was $3.340. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.02 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


NovoCure Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NovoCure's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Cyclically Adjusted PB Ratio Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.04

NovoCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 5.04 5.18

Competitive Comparison of NovoCure's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted PB Ratio falls into.



NovoCure Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NovoCure's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=17.99/3.02
=5.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NovoCure's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.34/131.7762*131.7762
=3.340

Current CPI (Mar. 2024) = 131.7762.

NovoCure Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 1.357 99.070 1.805
201503 0.000 99.621 0.000
201506 1.745 100.684 2.284
201509 1.466 100.392 1.924
201512 2.994 99.792 3.954
201603 2.611 100.470 3.425
201606 2.176 101.688 2.820
201609 1.845 101.861 2.387
201612 1.635 101.863 2.115
201703 1.463 102.862 1.874
201706 1.326 103.349 1.691
201709 1.306 104.136 1.653
201712 1.269 104.011 1.608
201803 1.174 105.290 1.469
201806 1.212 106.317 1.502
201809 1.236 106.507 1.529
201812 1.204 105.998 1.497
201903 1.321 107.251 1.623
201906 1.624 108.070 1.980
201909 1.924 108.329 2.340
201912 2.188 108.420 2.659
202003 2.411 108.902 2.917
202006 2.651 108.767 3.212
202009 3.018 109.815 3.622
202012 4.657 109.897 5.584
202103 3.606 111.754 4.252
202106 3.833 114.631 4.406
202109 3.980 115.734 4.532
202112 3.948 117.630 4.423
202203 4.169 121.301 4.529
202206 4.217 125.017 4.445
202209 4.244 125.227 4.466
202212 4.200 125.222 4.420
202303 4.070 127.348 4.212
202306 3.899 128.729 3.991
202309 3.688 129.860 3.742
202312 3.385 129.419 3.447
202403 3.340 131.776 3.340

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NovoCure  (NAS:NVCR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NovoCure Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (NovoCure) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.
Executives
Pritesh Shah officer: Chief Commercial Officer C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Michal Nath Puri officer: Chief Human Resources Officer BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039
Wilhelmus Cm Groenhuysen officer: Chief Financial Officer C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654
Ashley Cordova officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
Arye Barak Ben officer: General Counsel TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Kristin Stafford director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Frank X Leonard officer: President, CNS Cancers US 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355
William Patrick Burke officer: Chief Human Resources Officer 195 COMMERCE WAY, PORTSMOUTH NH 03801
Uri Weinberg officer: Chief Innovation Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355
Allyson J Ocean director 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087
Asaf Danziger director, officer: Chief Executive Officer 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302
Ely Benaim officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
William F Doyle director, 10 percent owner
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025